Q2 revenue up 16%, net profit up 51%, cash flow strengthens
ALIVUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Alivus reported unaudited results for the quarter ended September 30, 2026. Revenue from operations was Rs 6,819.87 million, up 16.0% year on year, and net profit rose 51.3% to Rs 1,967.45 million. In the half year, revenue was Rs 13,224.01 million, up 11.1%, and net profit was Rs 3,568.21 million, up 41.8%. Operating cash flow for the half year rose to Rs 4,596.91 million from Rs 2,607.29 million. The auditor gave an unmodified limited review.
Strong profit growth, wider margins and better cash generation are positive for share sentiment, supported by an unmodified auditor review.